Leverone Jason A. 4

What Happened
Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics (OKUR), had 301 shares disposed of on 2026-03-23 in an open-market/private sale. The shares were sold at a weighted average price of $4.16 per share for a total of approximately $1,251. This sale was an automatic disposition to satisfy tax withholding tied to the vesting of restricted stock units (RSUs), not an independent decision to sell shares for investment purposes.

Key Details

• Transaction date: 2026-03-23; filing date: 2026-03-24 (appears timely).
• Shares sold: 301; weighted average sale price: $4.16; total proceeds: ~$1,251.
• Footnote highlights:
  • F1: Shares were automatically sold to cover tax withholding on RSU vesting (Issuer’s 2023 RSU Plan).
  • F2: Sale executed in multiple trades at prices between $3.995 and $4.235; $4.16 is the weighted average.
  • F3: The underlying securities were RSUs (each RSU converts to one share upon vesting).
• Shares owned after the transaction: Not specified in the provided filing.

Context
This was a tax-withholding sale tied to RSU vesting (transaction code typically F), which is a routine administrative event and not necessarily a signal of the CFO’s view on company prospects. For derivative-related activity: RSUs vested and a portion of shares were sold automatically to cover taxes rather than a market-driven sale by the insider.